What is the difference between PEG-MGF and Tesamorelin?

PEG-MGF: PEG-MGF is Mechano Growth Factor (MGF) conjugated to a polyethylene glycol (PEG) polymer chain. The PEGylation dramatically extends the half-life from ~5 minutes (native MGF) to approximately 24–72 hours, allowing less frequent dosing and systemic distribution rather than purely local action. This trade-off — longer duration vs localized intensity — makes PEG-MGF a different tool than native MGF, better suited for systemic muscle recovery support and convenience-focused protocols. Tesamorelin: Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved in 2010 as Egrifta, it is the only GHRH peptide with an approved clinical indication — reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy. It has the most robust human trial evidence of any growth hormone secretagogue, including dedicated studies on visceral fat and liver fat. Both are in the Performance & Growth Hormone category but differ in mechanism, dosing, and research evidence — see the full comparison.

Can you take PEG-MGF and Tesamorelin together?

There is no specific, well-documented interaction rule for combining PEG-MGF and Tesamorelin in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, PEG-MGF or Tesamorelin?

PEG-MGF is currently preclinical only and Tesamorelin is fda-approved. "Better researched" depends on your research goal — review each profile's cited sources.

Performance & Growth Hormone · Comparison

PEG-MGF vs Tesamorelin

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

PEG-MGF

Preclinical only

PEG-MGF is Mechano Growth Factor (MGF) conjugated to a polyethylene glycol (PEG) polymer chain. The PEGylation dramatically extends the half-life from ~5 minutes (native MGF) to approximately 24–72 hours, allowing less frequent dosing and systemic distribution rather than purely local action. This trade-off — longer duration vs localized intensity — makes PEG-MGF a different tool than native MGF, better suited for systemic muscle recovery support and convenience-focused protocols.

Full profile

Tesamorelin

FDA-approved

Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved in 2010 as Egrifta, it is the only GHRH peptide with an approved clinical indication — reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy. It has the most robust human trial evidence of any growth hormone secretagogue, including dedicated studies on visceral fat and liver fat.

Full profile

	PEG-MGF	Tesamorelin
Category	Performance & Growth Hormone	Performance & Growth Hormone
Also known as	PEGylated Mechano Growth Factor, Polyethylene Glycol-MGF, Long-acting MGF	Egrifta, Egrifta SV, TH9507, GHRH analog
Evidence	Preclinical only	FDA-approved
Dosing range	100mcg–400mcg mcg, 2x weekly (Monday/Thursday or similar split)	1.28mg–2mg mg, once daily (subcutaneous)
Administration	Subcutaneous injection (preferred for systemic distribution), Intramuscular injection	Subcutaneous injection (abdomen, with site rotation)
Key side effects	Hypoglycemia (less pronounced than IGF-1 DES, more than native MGF due to systemic distribution), Generalized fatigue on injection days, PEG accumulation concern with very high doses over long periods (theoretical — not established at research doses), Localized injection site swelling	Injection site reactions (erythema, pruritus), Peripheral edema, Arthralgia (joint pain), Myalgia
Cited sources	2 references	5 references

Key differences

Evidence level differs: PEG-MGF is preclinical only, while Tesamorelin is fda-approved.
Administration: PEG-MGF — Subcutaneous injection (preferred for systemic distribution), Intramuscular injection; Tesamorelin — Subcutaneous injection (abdomen, with site rotation).
Dosing units differ: PEG-MGF is dosed in mcg, Tesamorelin in mg — they operate at different scales.
Frequency: PEG-MGF is typically 2x weekly (Monday/Thursday or similar split); Tesamorelin is once daily (subcutaneous).
Research depth: this profile cites 2 sources for PEG-MGF vs 5 for Tesamorelin.

How each works

PEG-MGF

PEGylation is a validated pharmaceutical strategy for extending peptide half-life (used in Pegasys/interferon, Somavert/pegvisomant, and others). The PEG chain shields the MGF peptide from proteolytic degradation and slows renal clearance. Research in rodent models confirms PEG-MGF preserves the biological activity of native MGF (satellite cell activation, muscle repair) with extended duration. Unlike native MGF which requires precise post-workout injection timing, PEG-MGF can be injected on a scheduled basis and still achieves systemic muscle-wide satellite cell effects.

Tesamorelin

Tesamorelin stimulates pulsatile growth hormone (GH) release from the pituitary, raising serum IGF-1 and preferentially reducing visceral adipose tissue (VAT). FDA-registration trials (Falutz et al., NEJM 2007; JAIDS 2010) showed ~15% VAT reduction versus placebo over 26 weeks. Later randomized trials (Stanley et al., JAMA 2014; Lancet HIV 2019) extended the evidence to liver fat, showing meaningful reductions in hepatic fat fraction and attenuated fibrosis progression in HIV-associated NAFLD.

Read the full PEG-MGF profile Read the full Tesamorelin profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.